3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 1
3
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Carcinoma, Hepatocellular
28
Breast Neoplasms
26
Small Cell Lung Carcinoma
20
Lung Neoplasms
20
Triple Negative Breast Neoplasms
18
Urinary Bladder Neoplasms
17
Neoplasms
16
Carcinoma, Transitional Cell
16
Neoplasm Metastasis
15
Melanoma
15
Colorectal Neoplasms
15
Uterine Cervical Neoplasms
11
Carcinoma, Renal Cell
10
Stomach Neoplasms
7
Recurrence
7
Head and Neck Neoplasms
7
Prostatic Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Mesothelioma, Malignant
5
Liver Neoplasms
5
Carcinoma, Squamous Cell
5
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Merkel Cell
4
Biliary Tract Neoplasms
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Thoracic Neoplasms
3
Interventions
Cyclophosphamide
155
Rituximab
148
Etoposide
84
fludarabine phosphate
73
Peripheral Blood Stem Cell Transplantation
68
Mycophenolic Acid
63
Busulfan
62
Filgrastim
59
Melphalan
58
Tacrolimus
54
Whole-Body Irradiation
51
Cytarabine
46
fludarabine
45
Radiotherapy
43
Methotrexate
41
Granulocyte Colony-Stimulating Factor
41
Cyclosporine
41
Vincristine
35
Antilymphocyte Serum
35
Carmustine
33
Doxorubicin
29
Prednisone
26
Thiotepa
25
Bendamustine Hydrochloride
24
Methylprednisolone
22
Ifosfamide
22
Dexamethasone
22
thymoglobulin
21
sargramostim
20
plerixafor
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Non-Hodgkin
×
atezolizumab
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled